Time to look Beyond Compulsory Licenses? A Glimpse at the Ribociclib Case
SpicyIP
OCTOBER 31, 2023
Image from here Recently, the Print reported that Novartis and Eli Lilly have voiced their opposition to the idea of compulsory licensing (“ CL ”) for breast cancer medications, Ribociclib and Abemaciclib. million breast cancer cases are expected globally by 2050. It also says that no licenses were given out. of GDP in FY23.
72 
Let's personalize your content